Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2020

Feb 12, 2021

SELL
$12.02 - $24.71 $15.3 Million - $31.4 Million
-1,271,985 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$4.25 - $14.19 $5.41 Million - $18 Million
1,271,985 New
1,271,985 $18 Million

Others Institutions Holding CRDF

About Cardiff Oncology, Inc.


  • Ticker CRDF
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,334,900
  • Market Cap $188M
  • Description
  • Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...
More about CRDF
Track This Portfolio

Track Vr Adviser, LLC Portfolio

Follow Vr Adviser, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vr Adviser, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Vr Adviser, LLC with notifications on news.